Bloomlife combines connected devices with data analytics to increase access to care, provide personalized feedback to moms, and help doctors earlier predict and manage pregnancy complications. At the center of our solution is a prenatal wearable that tracks critical health parameters of maternal and fetal health. Through our connected care platform we are aggregating first of its kind longitudinal data for digital biomarker discovery to improve risk stratification.  

Bloomlife is a clinical stage women’s health company developing remote prenatal care solutions for the 20% of high risk pregnancies that drive 60% of the $110B annual US healthcare spend. We combine connected devices with data analytics to increase access to care, provide personalized feedback to moms, and help doctors earlier predict and manage pregnancy complications. At the center of our solution is a prenatal wearable that tracks critical health parameters of maternal and fetal health. By addressing modifiable risk factors, detecting abnormalities, and predicting adverse events Bloomlife aims to ensure every family gets a healthy start.

Bloomlife has been recognized for its revolutionary vision and potential to impact lives globally, most recently receiving innovation awards and grants from Johnson & Johnson, Fast Company World Changing Ideas, Maternal and Child Health Bureau, National Science Foundation, and the European Commission Horizon 2020 Initiative.

100Plus is the leading AI-assisted remote patient monitoring (RPM)platform. We empower healthcare providers 

to remotely manage chronic conditions, improve patient adherence, reduce hospitalizations & support practices with our end-to-end solution. AI-assisted technology, Esper, improves care coordination & reduces administrative burden.

The leader in connective care solutions to support low-acuity monitoring and aging in place; remote patient monitoring; and chronic condition management.

Current antepartum fetal monitoring requires weekly trips to the clinic which is time consuming and inconvenient. For women in underserved communities difficulty accessing care can lead to poor adherence to screening guidelines.

By shifting antepartum fetal monitoring to the home, Bloomlife saves patients time and money, increases adherence to screening guidelines, and frees up valuable clinical resources.

Unlike the competition, Bloomlife does not require messy gels making the product experience more convenient for patients.

Not applicable

Artificial Intelligence underpins our integrated RPM platform by increasing patient adherence.